Abstract:Objective To control the quality ofFici Hirtae Radix by establishing quality standards.Methods The origin mistakes of Fici Hirtae Radix in Chinese Pharmacopoeia (1977 edition) were modified by searching and mining plant morphology characters,distribution of origin,historical evolution,clinical efficacy and modem research,medicinal standards in different regions on Ficus hirta Vahl and Ficus simplicissima.Morphological identification,microscopical characteristics based on transverse section and powder,and thin layer chromatography were adopted to identify commercial medicinal materials ofFici Hirtae Radix from different sources.The content of psoralen and bergapten was determined by HPLC.Moisture content,total ash,acid-insoluble ash,and ethanol-soluble extractives were determined by methods described in appendices of Chinese Pharmacopoeia (2010 edition).Results The origin of Fici Hirtae Radix was not F.simplicissima Lour.,but F.hirta Vahl.This study collected 20 Fici Hirtae Radix commercial medicines mixed 40％ non-medicinal parts samples.TLC data,morphological characteristics and microscopic characteristics,both showed obvious distinction.The concentration ofpsoralen and bergapten showed the content ofpsoralen range from 0.008 48％ to 0.150％,and the content of bergapten range from 0.005 87％ to 0.026 3％,and the contents of two index components ofFici Hirtae Radix were significantly higher than the non-medicinal parts samples.The moisture content ranged from 4.73％ to 8.27％,total ash ranged for 2.58％ to 4.37％,acid insoluble ash ranged for 0.054％ to 0.710％,ethanol-soluble extracts ranged for 6.23％ to 8.34％.Conclusion This paper revised the origin error ofFici Hirtae Radix of Chinese Pharmacopoeia (1977 edition) that its specification medicinal part should be the roots ofF.hirta,and established quality standards ofFici Hirtae Radix,and these methods could comprehensively and effectively control the quality of commercial medicinal materials ofFici Hirtae Radix.This study could provide evidence for rational,safe,and effective clinical application ofFici Hirtae Radix.

Study on Quality Standard for Fengshi Antai Tablets

Study on quality standards for Lingmaoxiang Jiedu pills

[Study on Quality Standard of Yixin Tablet].

Study on Revised Quality Standards of Fukangning Tablets

Study on Improving Quality Standard for ZhiSouDingChuan Pills

Study on Quality Standards of Xiao'er Changweikang Granules

Research Progress on Quality Control Methods for Xiaochaihu Preparations

Quality Control of Liujun Shengfa Tablets

Study on quality standard of Fici Hirtae Radix

Quality Standard Study of Xiaoyao Capsules

Studies on elevating quality standard of Shanzha Neixiao Pills

Study on qualification standards of Jianweizhengchang Pills

Development of a method using high-performance liquid chromatographic fingerprint and multi-ingredients quantitative analysis for the quality control of Yangxinshi Pian.

Qualitative and quantitative analysis of major components of Qiye Shen'an tablet by UPLC Q-TOF/MS and UPLC-TQS-MS/MS

Study on Quality Standard for Qiankun Liquid

Studies on Qualitative and Quantitative Methods of Liangge Pills

A strategy takes "Yiqing" tablets as an example to carry out simpler multi-component quantification and use fingerprint technology for comprehensive quality consistency evaluation

Studies on Quality Control of Shouwu Qiling Capsule

Quality Standards of Alpiniae Oxyphyllae Fructus

The Quality Study of the Shexiang Baoxin Pill

Qualitative and quantitative analysis of multiple components for quality control of Deng-Zhan-Sheng-Mai capsules by ultra high performance liquid chromatography tandem mass spectrometry method coupled with chemometrics.